PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)

This prospective clinical study aims to evaluate the predictive power of PSMA PET imaging in patients with advanced prostate cancer who are receiving systemic drug therapies. The primary goal is to identify prognostic factors derived from PSMA PET imaging. These factors include the number of cancer lesions, the size of the tumor, and measurements known as SUVmax and SUVmean. By identifying these factors, the investigators aim to better group patients and predict those who may have a less favorable outcome. While PSMA PET imaging is highly accurate in locating cancer sites within the body, its ability to predict treatment response has not yet been thoroughly studied in a prospective manner for this patient population. This study will assess the predictive role of PSMA PET imaging and its ability to forecast treatment response across a range of systemic therapies, including hormone therapy and chemotherapy, in patients with both hormone-sensitive (HSPC) and castration-resistant (CRPC) prostate cancer.

NCT Number	NCT07089550
Lead Sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna Collaborators: Ospedale Policlinico San Martino, Ospedale Santa Croce-Carle Cuneo, Azienda Ospedaliera Universitaria Policlinico "G. Martino"
Conditions	PSMA Positive Tumors or Tumor Tissues, Prostate Cancer Metastatic
Enrollment	1,300 participants
Start Date	2025-04-02
Primary Completion	2034-04-26 (estimated)
Study Completion	2034-04-26 (estimated)
Updated on ClinicalTrials.gov	2026-02-20